SEC Filing Summary: CryoLife, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for CryoLife, Inc. for the period ended June 30, 2003. The company provides human tissue preservation services and implantable medical devices. The reporting period is heavily impacted by an August 2002 FDA Order regarding tissue processing, reported tissue infections, and subsequent adverse publicity, which have significantly reduced demand and revenues.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2003 |
6 Months Ended June 30, 2003 |
6 Months Ended June 30, 2002 |
|---|---|---|---|
| Total Revenues | $15,713 | $31,633 | $48,735 |
| Net Loss | $(22,346) | $(22,780) | $(2,418) |
| Net Loss Per Share (Basic/Diluted) | $(1.14) | $(1.16) | $(0.13) |
| Cash and Cash Equivalents | $16,147 | $16,147 | $12,290 |
| Marketable Securities | $9,761 | $9,761 | $14,583 |
| Total Current Assets | $52,647 | $52,647 | $61,447 |
| Total Current Liabilities | $31,812 | $31,812 | $23,862 |
| Net Working Capital | $20,835 | $20,835 | $37,585 |
| Net Cash from Operating Activities | N/A | $2,975 | $750 |
Debt and Liquidity: The company has a Term Loan with a principal balance of $4.8 million. As of June 30, 2003, the company is in violation of debt covenants (debt coverage ratio and net worth) and has been notified by the lender of an event of default. The lender is negotiating a forbearance agreement that may require a balloon payment of the full balance by October 31, 2003. The company also has $1.6 million in notes payable for insurance premiums.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 32% for the quarter and 35% for the six months ended June 30, 2003, compared to the prior year. "Adjusted revenues" (excluding recall adjustments) decreased 39% and 40%, respectively.
- Segment Performance:
- Human Tissue Preservation: Revenues dropped 51% (quarter) and 53% (six months). Orthopaedic tissue revenues fell 95% due to processing cessation and FDA restrictions. Vascular revenues fell 29% (quarter) and 35% (six months). Cardiovascular revenues fell 31% (quarter) and 33% (six months).
- Products (BioGlue): Revenues increased 27% (quarter) and 32% (six months), partially offsetting the decline in tissue services.
- Expense Surge: General, administrative, and marketing expenses increased 106% for the quarter and 68% for the six months. This was driven by a $9.0 million accrual for product liability claims in excess of insurance coverage and a $3.9 million accrual for unreported product liability claims.
- Asset Write-downs: The company recorded $1.1 million (quarter) and $1.4 million (six months) in write-downs of deferred preservation costs. In the prior year, write-downs were significantly higher ($10.0 million in Q2 2002) due to the initial FDA Order.
- Tax Provision: The company recorded a $11.4 million valuation allowance against deferred tax assets in Q2 2003, resulting in an income tax expense of $6.1 million for the quarter, despite operating losses.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects liquidity to decrease significantly over the next 12 months due to lower revenues, higher processing costs, and legal expenses. The company believes it can meet liquidity needs through June 30, 2004, but may require additional financing thereafter.
- Revenue Outlook: Management believes Q3 2003 revenues will exceed Q3 2002 levels but expects full-year 2003 revenues to be significantly lower than 2002. Orthopaedic revenues are expected to increase slowly but remain minimal.
- Regulatory Risks:
- FDA Order: Restrictions on non-valved cardiac, vascular, and orthopaedic tissues processed between Oct 2001 and Sept 2002 remain. An agreement with the FDA allows limited distribution under strict conditions, expiring Sept 5, 2003.
- SynerGraft Technology: The FDA requires premarket approval for SynerGraft processed tissues. The company has voluntarily suspended use of this technology until resolved, which will adversely affect margins in Q3 and Q4 2003.
- Legal and Litigation:
- Product Liability: Approximately 21 lawsuits are open. The company has accrued $9.0 million for known claims and $7.5 million for unreported claims. Insurance coverage is disputed by an upper-layer carrier, potentially leaving the company exposed to significant uninsured losses.
- SEC Investigation: The SEC inquiry into the company's disclosures regarding the FDA recall became a formal investigation in June 2003.
- Class Action: A consolidated securities class action lawsuit is in the discovery phase.
- Debt Default: The company is in default on its Term Loan due to covenant violations and the FDA Order. A forbearance agreement is being negotiated, which may require full repayment by October 31, 2003.
Key Facts for Investor Verification
- Debt Repayment Capability: Verify the company's ability to repay the $4.8 million Term Loan balloon payment by October 31, 2003, given the current cash balance of $16.1 million and ongoing cash burn.
- Insurance Coverage Dispute: Confirm the status of the dispute with the upper-layer excess product liability carrier regarding the exclusion of 11 matters, which could materially increase the company's uninsured liability.
- Orthopaedic Revenue Recovery: Monitor the resumption of orthopaedic tissue shipments and the actual demand recovery, as this segment has seen a 95% revenue decline.
- SEC Investigation Outcome: Track the progress of the formal SEC investigation and the consolidated securities class action lawsuit for potential financial penalties or reputational damage.
- FDA Agreement Renewal: Watch for the renewal status of the FDA Agreement expiring September 5, 2003, and any new regulatory actions regarding SynerGraft technology.